论文部分内容阅读
目的探讨依那西普联合甲氨蝶呤治疗类风湿性关节炎的临床疗效。方法将98例类风湿性关节炎患者分为观察组(50例)及对照组(48例),两组患者均应用甲氨蝶呤治疗,观察组患者加用依那西普(益赛普),连续治疗12周,治疗前后对患者行白介素-1(IL-1)、肿瘤坏死因子(TNF)、超敏C反应蛋白(hs-CRP)检查,比较两组患者主要症状变化及实验室检查结果。结果观察组患者关节疼痛、关节肿胀、晨僵等主要症状改善优于对照组(P<0.05);观察组患者IL-1、TNF、hs-CRP下降明显,与对照组患者比较差异有统计学意义(P<0.05)。结论依那西普联合甲氨蝶呤治疗类风湿性关节炎疗效优于单纯甲氨蝶呤,效果满意。
Objective To investigate the clinical efficacy of etanercept combined with methotrexate in the treatment of rheumatoid arthritis. Methods 98 patients with rheumatoid arthritis were divided into the observation group (50 cases) and the control group (48 cases), both groups were treated with methotrexate, the observation group patients with etanercept ) For 12 weeks. The levels of IL-1, TNF and hs-CRP were measured before and after treatment. The main symptoms and the changes of the laboratory symptoms in the two groups were compared test result. Results The improvement of the main symptoms such as joint pain, joint swelling and morning stiffness in the observation group was better than that in the control group (P <0.05). The levels of IL-1, TNF and hs-CRP in the observation group decreased significantly compared with those in the control group Significance (P <0.05). Conclusion Etanercept and methotrexate are superior to methotrexate in the treatment of rheumatoid arthritis with satisfactory results.